CYP2R1 polymorphisms are important modulators of circulating 25-hydroxyvitamin D levels in elderly females with vitamin insufficiency, but not of the response to vitamin D supplementation.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

The study group was 96 men.

The age groups tagged for this paper are older adults, both men and women.

How the Study Was Run

The design is described as randomized and double-blind.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the men nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Genotyping was performed for rs12794714, rs10741657, rs1562902, and rs10766197 SNPs using real-time PCR.

The 25(OH)D levels were measured by liquid chromatography tandem mass spectrometry.

What Was Measured

Topics PubMed links to this paper include Cholecalciferol, Cholestanetriol 26-Monooxygenase, Cytochrome P450 Family 2, Dietary Supplements, Genetic Predisposition to Disease, Genotype and Polymorphism, Single Nucleotide.

Author keywords: 25(OH) vitamin D, CYP2R1, Genetic polymorphisms, Metabolic pathway and Vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 96 men.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.